Skip to Content
Still using that old version of Internet Explorer? This site will work much better in a newer version of IE or Firefox.
Download Internet Explorer 8 or Firefox 3 now!

vaccines

Pneumococcal Conjugate Vaccine Impact Study (PCVIS)

Principal Investigator(s): 
Anthony Scott
Other Investigator(s): 
Susan Morpeth
Other Investigator(s): 
Laura L Hammitt

No description available.

Francis Ndungu

francis-ndungu.jpg
Email: 
fndunguatkilifi [dot] kemri-wellcome [dot] org
Group: 
Molecular Parasitology and Immunology

Immunity to malaria is slow to develop, is non-sterilising and wanes rapidly when immune adults migrate to non-endemic regions, suggesting that specific problems exist in the establishment and main

Margaret Mackinnon

mmackinnon-head.jpg
Email: 
mmackinnonatkilifi [dot] kemri-wellcome [dot] org
Group: 
Molecular Parasitology and Immunology

What is it that causes pathogens to harm their host? In my lab, we study the evolutionary pressures, and the biology underlying them, that make pathogens virulent.

Anthony Scott

Anthony Scott.jpg
Email: 
ascottatkilifi [dot] kemri-wellcome [dot] org
Group: 
Epidemiological and Demographic Surveillance System (EPI-DSS)

Anthony Scott leads a programme of research studying invasive bacterial disease, principally pneumococcal disease.

Patricia Njuguna

Trust 12.jpg
Email: 
pnjugunaatkilifi [dot] kemri-wellcome [dot] org
Group: 
Clinical Group

Patricia Wambui Njuguna is Paediatrician based in Kilifi, Kenya. She graduated with a Masters in Medicine (Paediatrics and Child Health) (University of Nairobi) in 2006.

Moses Ndiritu Ndirangu

moses-ndirangu.jpg
Group: 
Child and Newborn Health Group

Moses completed his Masters in Epidemiology at the University of Cambridge and joined KEMRI/Wellcome Trust Research Programme, Kilifi in November 2003.

Identifying the merozoite targets of naturally acquired immunity to malaria

Principal Investigator(s): 
Faith Osier

We are currently studying antibody responses to a panel of merozoite antigens that are leading candidates for malaria blood stage vaccines including Merozoite surface proteins (MSP) -1, -2 and -3, Apical membrane antigen 1 (AMA-1), Erythrocyte binding antigen 175 (EBA-175) and Glutamate rich protein (GLURP).

Reactogenicity and immunogenicity of 10-valent pneumococcal conjugate vaccine in children

Full Title: 
Reactogenicity and immunogenicity of 10-valent pneumococcal conjugate vaccine in children aged 12-59 months
Principal Investigator(s): 
Laura L Hammitt

No description available.

Laura L Hammitt

Scan20001.JPG
Email: 
lhammittatkilifi [dot] kemri-wellcome [dot] org
Group: 
Epidemiological and Demographic Surveillance System (EPI-DSS)